Vixtimotamab (AMV-564, TandAb T564), a bispecific tetravalent tandem diabody (TandAb), selectively targets human CD33 and CD3 antigens, and is used in acute myeloid leukemia (AML) research [1].
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted